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Introduction
============

Despite advances in technology for the treatment of cardiogenic shock, mortality has not dramatically improved \[[@REF1]\]. Cardiogenic shock primarily occurs in the setting of acute myocardial infarction. Standard of care in acute myocardial infraction complicated by cardiogenic shock is revascularization \[[@REF2]\]. Percutaneous mechanical circulatory support devices, such as the Impella-CP (Abiomed, Danvers, MA), are used as supportive therapy in cardiogenic shock, despite limited randomized clinical data \[[@REF3]\]. Registry data do suggest improved outcomes in cardiogenic shock supported by the Impella-CP \[[@REF4]\]. However, there is a paucity of data surrounding outcomes in cardiogenic shock patients with concurrent acute kidney injury (AKI), managed with or without renal replacement therapy (RRT). Cardiogenic shock complicated by AKI requiring RRT is associated with increased mortality \[[@REF5],[@REF6]\]. We hypothesize that early RRT for AKI in cardiogenic shock patients on Impella-CP improves survival.

Materials and methods
=====================

Our cohort was a single-center retrospective study including all patients on Impella-CP for cardiogenic shock admitted to Albany Medical Center between January 2015 and December 2017. Data were obtained by a retrospective review of the electronic medical record. Cardiogenic shock was defined as elevated serum lactate (\>2.0 mmol/L) and hypotension requiring inotrope/vasopressors to maintain a mean arterial blood pressure above 65 mmHg. Eligible patients were classified based on AKI at presentation (increase in serum creatinine\>0.3 mg/dL from baseline); those with AKI were further categorized by RRT. This led to three groups: no AKI, AKI minus RRT, and AKI plus RRT. RRT included hemodialysis or continuous RRT.

The exclusion criteria included pre-existing hemodialysis-dependent patients, unknown baseline renal function, or patients lost to follow-up within 30 days. The chi-square test was utilized to compare 30-day mortality of AKI plus RRT and no AKI groups as well as AKI minus RRT and no AKI groups. Continuous variables (lab parameters at presentation) were compared between groups using ANOVA. Type 1 error was prespecified at less than or equal to 5%. The protocol was approved by the Institutional Review Board at Albany Medical Center.

Results
=======

Between January 2015 and December 2017, 34 patients with cardiogenic shock on Impella-CP met the inclusion criteria for our study. There were 13 patients with no AKI, 9 had AKI plus RRT, and 12 had AKI minus RRT. The only indication for RRT was AKI not responding to diuretics (oliguria or anuria). Baseline characteristics and lab parameters at presentation are included in Tables [1](#TAB1){ref-type="table"}, [2](#TAB2){ref-type="table"}.

###### Lab parameters at presentation (±SEM)

SEM, standard error of the mean; AKI, acute kidney injury; RRT, renal replacement therapy; INR, international normalized ratio. \*Renal replacement therapy (hemodialysis or continuous renal replacement therapy).  

  -------------------------- ------------- ------------------- ------------ ---------
                             no-AKI        AKI without RRT\*   AKI+RRT\*    p-value
  Hemoglobin (g/dL)          13.2±0.529    12.1±0.583          12.9±1.46    0.448
  Serum creatinine (mg/dL)   0.972±0.071   2.10±0.320          2.55±0.918   0.010
  Serum lactate (mmol/L)     5.82±4.01     4.73±0.628          4.75±0.329   0.904
  Serum HCO~3~ (mEq/L)       20.9±1.42     19.7±1.40           19.7±2.78    0.773
  INR                        1.96±0.529    1.70±0.416          1.67±0.509   0.929
  Arterial blood gas                                                        
  pH                         7.20±0.053    7.28±0.024          7.18±0.055   0.466
  pCO~2~                     47.0±5.24     41.8±2.63           51.0±9.43    0.687
  pO~2~                      146±46.9      163±41.2            95.2±18.4    0.526
  -------------------------- ------------- ------------------- ------------ ---------

###### Baseline characteristics

AKI, acute kidney injury; HTN, hypertension; DM, diabetes mellitus; CVA/TIA, cerebrovascular accident/transient ischemic attack; GFR, glomerular filtration rate; PCI, percutaneous coronary intervention; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; NSAID, non-steroidal anti-inflammatory drug.

  -------------------------------------- ------------------------------------- ---------------------------------------- ---------
                                         Cardiogenic shock with AKI n=21 (%)   Cardiogenic shock without AKI n=13 (%)   p-value
  Age (years±SD)                         60.7±14.5                             63.3±11.8                                0.556
  Female                                 2 (9.52)                              3 (23.1)                                 0.455
  HTN                                    15 (71.4)                             8 (61.5)                                 0.428
  DM                                     5 (23.8)                              3 (23.1)                                 0.858
  Dyslipidemia                           11 (52.4)                             7 (53.8)                                 0.985
  CVA/TIA                                3 (14.3)                              2 (15.4)                                 0.781
  GFR\<60 mL/min/1.73 m^2^               4 (19.0)                              1 (7.69)                                 0.211
  Anemia (Hb\<11 g/dL)                   7 (33.3)                              0 (0)                                    0.008
  Atrial fibrillation                    4 (19.0)                              2 (15.4)                                 0.873
  Peripheral vascular disease            4 (19.0)                              3 (23.1)                                 0.841
  Valvular heart disease                 5 (23.8)                              2 (15.4)                                 0.497
  Coronary artery disease                9 (42.9)                              5 (38.5)                                 0.790
  Prior PCI                              7 (33.3)                              6 (46.2)                                 0.459
  Tobacco use in prior 12 months         7 (33.3)                              5 (38.5)                                 0.825
  Medication use prior to presentation                                                                                  
  ACEi/ARB                               10 (47.6)                             6 (46.2)                                 0.985
  Beta blocker                           11 (52.4)                             5 (38.5)                                 0.515
  Calcium channel blocker                0 (0)                                 3 (23.1)                                 0.044
  Diuretics                              10 (47.6)                             4 (30.8)                                 0.341
  Aspirin                                11 (52.4)                             5 (38.5)                                 0.515
  NSAID                                  1 (4.76)                              0 (0)                                    0.283
  Digoxin                                0 (0)                                 1 (7.69)                                 0.168
  Statin                                 12 (57.1)                             5 (38.5)                                 0.316
  Metformin                              2 (9.52)                              3 (23.1)                                 0.455
  -------------------------------------- ------------------------------------- ---------------------------------------- ---------

AKI was associated with higher 30-day mortality compared to patients with no AKI in our cardiogenic shock cohort \[52.4% (11/21) vs. 30.8% (4/13), p=0.01; relative risk \[RR\] 6.16 (95% confidence interval \[CI\] 1.41-26.7)\]. Thirty-day mortality was similar in patients with no AKI and AKI plus RRT \[30.8% (4/13) vs. 22.2% (2/9), p=0.48; RR 2.25 (95% CI 0.22-22.1)\]. Patients with AKI minus RRT had a higher 30-day mortality than patients with no AKI \[75.0% (9/12) vs. 30.8% (4/13); p=0.03; RR 6.75 (95% CI 1.16-39.2)\]. Outpatient use of calcium channel blockers and hemoglobin greater than 11 g/dL were associated with decreased likelihood of AKI at presentation (Table [1](#TAB1){ref-type="table"}). Serum creatinine at presentation was higher in patients who received RRT for AKI; serum lactic acid, hemoglobin, and arterial pH were similar across all groups (Table [2](#TAB2){ref-type="table"}).

Discussion
==========

AKI in severe system illness and particularly cardiogenic shock is associated with poor outcomes \[[@REF7],[@REF8]\]. AKI in cardiogenic shock has been postulated to be caused by venous congestion and reduced renal perfusion \[[@REF9]\]. 

Our single-center retrospective study evaluated outcomes of cardiogenic shock in patients on Impella-CP complicated by AKI with and without RRT. We found that patients with AKI had a similar 30-day mortality when receiving RRT compared to patients without AKI at presentation.

It seems intuitive that early recognition of AKI in cardiogenic shock and aggressive treatment with RRT may improve outcomes, but data are conflicting. Aside from cardiogenic shock populations, the Impella-CP device is shown to be protective against AKI in patients undergoing high-risk percutaneous coronary intervention \[[@REF10]\]. In a single-center study, patients on extracorporeal membrane oxygenation for cardiogenic shock with associated AKI did not have improved short-term survival with RRT \[[@REF11]\]. Whether this cohort was more critically ill than the patients we studied is not known.

The limitations of our study are acknowledged: small sample size, retrospective examination, single-center review, and wide confidence intervals.

Conclusions
===========

AKI is an independent predictor of mortality in cardiogenic shock. Based on our single-center, retrospective comparison of cardiogenic shock supported by Impella-CP, 30-day mortality was similar between patients with no AKI and those who received RRT for AKI. Early initiation of RRT for AKI coupled with improved left ventricular unloading with Impella-CP may offset the detrimental effects of AKI in cardiogenic shock. Our study provides preliminary evidence to warrant further investigation on early RRT for AKI in cardiogenic patients supported with Impella-CP.
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